key: cord-0686634-9k7uvvxm authors: Gholami, Nasrin; Amzajerdi, Vahid Sheykhzadeh; Mehdioghli, Rahim; Heris, Hengameh Khadivi; Kazempour, Mona Jahandideh title: Isolated hyperbilirubinemia as the manifestation of acute liver failure in a patient with acute myelogenous leukemia and COVID-19 infection date: 2021-07-01 journal: Eur J Transl Myol DOI: 10.4081/ejtm.2021.9817 sha: e23a781c5e2a73c09622e256182bc51de99c294a doc_id: 686634 cord_uid: 9k7uvvxm Acute liver failure is a rare but catastrophic syndrome. Liver function tests usually reveal cholestatic or hepatocellular pattern, but in this case, we report a previously undescribed manifestation of this condition as isolated hyperbilirubinemia. Our patient was a 50 years old male who was diagnosed with acute myelogenous leukemia (AML(M4)). The patient had no history of liver disease and had normal liver function tests at the time of admission. After chemotherapy treatment, the patient developed signs of acute liver failure and had a rapid demise. After further investigations, we found two possible causes. Firstly, liver involvement of acute myelogenous leukemia (AML) which after induction chemotherapy is a rare condition and has high mortality rates despite treatment. Secondly, acute liver injury due to COVID-19 infection. signs and symptoms or abnormal liver function tests with a hepatocellular or a cholestatic pattern. 1 Isolated hyperbilirubinemia is a very rare manifestation to the best of our knowledge. Moreover, liver involvement with acute myelogenous leukemia (AML) has rarely been reported. Most reported cases of AML with liver involvement had an exacerbating disease course with a very poor outcome. 2, 3 Furthermore, it is known that viral infections play a major role in causing acute liver injury, especially in developing countries. 1 We could not find any trace of hepatotropic viruses in this case, but we found a COVID-19 infection which could be a risk factor or a comorbidity of acute liver failure. A 50 years old addicted (to edible opium) male with no significant past medical history was referred to our hematology department for investigations. The patient complained about a 2-months history of loss of appetite and 2-weeks of generalized ecchymotic and petechial skin lesions mostly on lower limbs. Laboratory analysis showed leukocytosis (WBC: 50 000 / mL) with thrombocytopenia (Plt: 12000 / mL) and anemia (Hb: 11 g/dL). The patient was admitted to the hematology ward with a possible diagnosis of Leukemia. After admission, the patient underwent bone marrow biopsy and bone marrow aspiration ( Figure 1 , upper left panel) which confirmed Acute Myelogenous Leukemia (M4, AML). On the 3rd day of admission, the induction chemotherapy with standard 7+3 regimen (7 days Cytarabine 100 mg/m², 3 days Idarubicin 12 mg/m²) was started. WBC count decreased rapidly, and on the 6th day after admission, the patient went in a deep neutropenic state with an average Absolute Neutrophil Count of 50 /mL. The bone marrow continued to be suppressed throughout the disease course. Platelet count (10000/mL on average) and hemoglobin levels (6-7 g/dL on average), remained low although the patient was receiving 10 units of platelets and 2 units of packed-cells daily. On the 12th day after admission, the patient developed mild jaundice, which was visibly progressive, and subjectively the patient became more icteric every day. In addition, the Bilirubin levels, especially conjugated bilirubin started to rise but curiously AST and ALT levels remained normal. Albumin levels dropped and the patient slowly developed progressive pitting edema which later transformed into severe anasarca edema. The administration of NAC was started. On the 16th day after admission, the patient developed signs of hepatic encephalopathy including Asterixis and altered sleep pattern so lactulose 30 cc TDS was prescribed. In addition, prothrombin time and INR began to elevate ( Figure 1, upper right panel) , subsequently, the infusion of 2 units of Fresh Frozen Plasma every 12 hours was started. Hbs-Ag, Hbs-Ab, HCV-Ab, HAV-Ab-IgM, HIV-Ab, CMV-Ab-IgM, EBV-Ab-IgM, HSV-I&II-Ab, ANA, AMA, ASMA were checked and they were all negative. Imaging studies were suggestive of moderate hepatomegaly with diffuse parenchymal infiltration. Due to the patient's thrombocytopenia and elevated prothrombin time, liver biopsy was not performed. On day 17 after admission, the O₂ saturations dropped to 70% and a chest CT-Scan was requested and done, which was suggestive of COVID-19 infection (Figure 1 . bottom left panel) and later the PCR test was positive for SARS-COV-2. On day 20, the patient was transported to the Intensive Care Unit and unfortunately, 2 days later expired due to multiple organ failure. The patient's family did not consent for an autopsy so it was not performed. The detailed trends of laboratory analises are shown in (Figure 1 , bottom right panel). Previous reports show either a cholestatic pattern or a transaminitis picture, 1-4 but in this case, we are reporting a previously undescribed isolated hyperbilirubinemia as the presentation of the acute liver failure in the setting of AML liver involvement. On another aspect, the patient tested positive for SARS-COV-2 which raised some questions about the causality, triggers, and risk factors of acute liver failure. Considering the rapid progress of hepatic failure, we speculated that COVID-19 infection could play a role in exacerbating or triggering the condition. In a large U.S. cohort study, Phipps et al., 5 demonstrated that acute liver injury is common in patients who test positive for SARS-COV-2, but it is most often mild. However, 6.4% of patients had a severe liver injury, with a severe disease course. 5 A largely hepatocellular pattern of liver injury with few patients with elevated bilirubin and/or elevated alkaline phosphatase was observed. Significant hypoalbuminemia was seen, particularly among patients with severe liver injury. They additionally report that bilirubin was often normal even in extreme cases, 5 unlike the situation of our patient. That cohort study shows a hepatocellular pattern as the manifestation of liver involvement in COVID-19 infection, 5 which differs from our case's presentation, but it also demonstrates that liver injury is common among COVID-19 patients. The mechanism of liver injury remains largely unknown and is thought to be a combination of both direct virally-mediated effects as well as a result of the immune response. 6, 7 Viral infections are predominant causes of acute liver failure in developing countries, especially hepatitis A, B, and E viruses. 1 It is clear that COVID-19 infection can also damage the liver tissue and in theory, it could at least worsen the progression of liver failure. However, it remains unclear if this infection could cause in the already susceptible liver to fail or it is a risk factor of fulminant hepatic failure. Isolated hyperbilirubinemia is a very rare presentation of the rare acute liver failure syndrome. In our investigations, we found two possible causes for this case. Firstly, AML involvement of the liver which is also uncommon. Secondly, COVID-19 infection which can cause liver injury. Or a combination of these two that eventually leads to this unique manifestation of this condition. In any case, future research with a large sample pool, case series, and longitudinal studies are required. Here are some of our recommended subjects for future research: i) isolated hyperbilirubinemia as oppose to cholestatic and hepatocellular patterns in acute liver failure; ii) liver involvement and acute liver failure in AML patients and the response to chemotherapy; iii) acute liver failure and it's risk factors in COVID-19 infection. Acute liver failure due to liver parenchymal infiltration with acute myelogenous leukaemia in a patient with myelodysplastic syndrome Acute myeloid leukemia presenting as obstructive jaundice Liver involvement with acute myeloid leukemia Acute myeloid leukemia presenting as obstructive jaundice COVID-19 and liver disease Acute liver failure Accepted for publication Funding None. The author declares no competing interests. We confirm that we have read the Journal's position on the issues involved in ethical publication and affirm that this report is consistent with those guidelines.